1273190-06-9

Upstream product

• 21803-75-8 4-amino-3-chlorobenzonitrile 
• 1273190-04-7 tert-butyl 5-chloro-3-formyl-6-methylpyrazolo[1,5-a]pyrimidin-7-yl(cyclopropyl)carbamate 
• 1273190-00-3 5-chloro-7-(cyclopropylamino)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbaldehyde 
• 1273190-02-5 5-chloro-N-cyclopropyl-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 57489-71-1 6-methylpyrazolo[1,5-a]pyrimidine-5,7-diol 
• 61098-38-2 5,7-dichloro-6-methyl-pyrazolo[1,5-a]pyrimidine 

Relevant academic research and scientific papers

Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

Pyrazolopyrimidin CK2 and related heterocyclic compound as an inhibitor

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS

The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders.